Login to Your Account



Better than Antibodies?

Plumbing RNAi's Potential: Medicines Co., Alnylam Join Up

By Randy Osborne
Staff Writer

Tuesday, February 5, 2013
The Medicines Co. likes Alnylam Pharmaceuticals Inc.'s RNA interference (RNAi) approach to blocking proprotein convertase subtilisin/kexin type 9 (PCSK9) enough to pay $25 million up front plus as much as $180 million in milestone payments, but how the method might stand up against late-stage antibodies remains to be seen clinically.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription